A Phase 3 interventional study of Oleogel-S10 ointment and Octenilin® wound gel in Burns, sponsored by Birken AG. Completed at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-28.
Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Burns with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Burns · Germany.
Among the 27 studies in Burns with a site in Germany, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 9th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →4 of the 27 studies in Burns with a site in Germany are open now. Recruiting first, the newest first:
CUTISS AG · Sites in Germany, Belgium, France and 6 more countries
Ages 12+
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+
University Hospital Bergmannsheil Bochum · Sites in Germany
Ages 18–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 8
First in 2005; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 80 across the 21 interventional studies, 84 across the 6 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Birken AG, one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
Birken AG is the lead sponsor of 6 studies on the registry; none are open to participants now.
Chiesi Farmaceutici S.p.A. has 1 study filed under Burns — fewer than ten, so there is no comparison to draw.
1 of the studies in Burns with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06745557Phase 3CUTISS AGPhase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Burns with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main goal of this phase III clinical trial is to show safety and efficacy of Oleogel-S10 in the acceleration of wound healing of grade 2a burn wounds.
Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in patients with skin lesions. Especially the results in the split-thickness skin graft donor site, which is regarded as an excellent model for any kind of superficial wounds in human skin, suggest that Oleogel-S10 should be efficacious and safe in treatment of grade 2a burns.
The present Phase III clinical trial in grade 2a burns is initiated in order to measure the wound healing progress applying objective methods, i.e., the time to healing and the grade of epithelialization of the wound.
In this study, grade 2a burn wounds are separated into two halves: Following wound cleaning and disinfection, wounds are separated into two wound halves. Randomly assigned, one wound half receives Oleogel-S10 ointment, the other wound half standard of care treatment.
Wound healing progress is documented by photos which are assessed by expert reviewers blinded to the treatment of the wound halves.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
Drug: Oleogel-S10 ointment · Device: Octenilin® wound gel
Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
Drug: Oleogel-S10 ointment · Device: Octenilin® wound gel
Drug pages: Episalvan · Birch triterpenes
Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
Also known as: Contains Octenidine
Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care
Photo-based evaluation by independent experts blinded to the treatment regime.
Time frame: 2 to 3 weeks
Intra-individual Difference in Time to Wound Closure Between Wound Halves, Either Treated With Oleogel-S10 or Treated With Standard of Care
Time frame: 2 to 3 weeks
Time From Study Start After Burn Accident Until Wound Closure is Achieved Separately for Wound Halves Treated With Oleogel-S10 vs. Standard of Care
Time frame: 2 to 3 weeks
Percentage of Patients With Wound Closure at Different Time Points
Time frame: 2 to 3 weeks
Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator
Time frame: 2 to 3 weeks
Likert Scale Rating of Efficacy (Evaluated by Both the Investigators and Patients)
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
Time frame: 2 to 3 weeks
Cosmetic Outcome After 3 and 12 Months After Burn Accident, in Relation to Texture, Redness, Growth of Hair and Pigmentation, Based on Blinded Photo Evaluation
Time frame: 3 and 12 months
Likert Scale Rating of Tolerance (Evaluated by Both the Investigators and Patients)
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
Time frame: 2 to 3 weeks
PK Data: Systemic Presence/Concentration of Betulin in Blood Plasma Samples
Time frame: 2 to 3 weeks
Microbial Colonization of the Wound Halves
Time frame: 2 to 3 weeks
Assessment of Adverse Events
Time frame: 2 to 3 weeks
Study participants were enrolled from 31-Aug-2012 to 10-Jul-2013, in 10 clinical centres in 4 countries: Germany (4 centers), Uk (3 centers), Sweden (2 centers), and Switzerland (1 center).
| Milestone | Entire Study Population |
|---|---|
| Started | 61 |
| Completed | 51 |
| Not completed | 10 |
| Withdrew: Adverse event | 6 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Violation of eligibility criteria | 1 |
| Withdrew: Change of therapy | 1 |
Photo-based evaluation by independent experts blinded to the treatment regime.
| percentage of patients | Entire Study Population |
|---|---|
| Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care | 85.7 (69.7 to 95.2) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
Results for this outcome have not been posted.
Results for this outcome have not been posted.
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Day 0 (start of treatment) till end of treatment (Day 21 or earlier if full wound closure was achieved earlier, or later, if the investigator decided to change medication and/or treatment due to unsatisfying wound closure after Day 21).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entire Study Population - Systemic AEs | — | 2/61 (3.3%) | 0/61 (0%) |
| Oleogel-S10 Localized AE | — | 1/61 (1.6%) | 0/61 (0%) |
| Octenilin Localized AE | — | 1/61 (1.6%) | 0/61 (0%) |
| Localized AE Both Wound Halves | — | 4/61 (6.6%) | 0/61 (0%) |
| Event | Entire Study Population - Systemic AEs | Oleogel-S10 Localized AE | Octenilin Localized AE | Localized AE Both Wound Halves |
|---|---|---|---|---|
| Condition aggravatedGeneral disorders | 0/61 | 0/61 | 0/61 | 2/61 |
| Wound infectionInfections and infestations | 0/61 | 0/61 | 0/61 | 2/61 |
| Wound necrosisInjury, poisoning and procedural complications | 0/61 | 1/61 | 0/61 | 0/61 |
| Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/61 | 0/61 | 0/61 | 0/61 |
| PyrexiaGeneral disorders | 1/61 | 0/61 | 0/61 | 0/61 |
| Soft tissue infectionInfections and infestations | 0/61 | 0/61 | 1/61 | 0/61 |
| Age, Categorical(Participants) | Entire Study Population |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 54 |
| >=65 years | 6 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Median | 41 (18 to 79) |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 19 |
| Male | 42 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| Sweden | 3 |
| United Kingdom | 28 |
| Switzerland | 4 |
| Germany | 26 |
The record gives a start of Aug 2012, a primary completion of Jul 2013 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Episalvan · Birch triterpenes